A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
Although challenging, the isolation of pulmonary endothelial cells is essential for studies on lung inflammation. The present protocol describes a procedure for the high-yield, high-purity isolation of macrovascular and microvascular endothelial cells.
The availability of cells isolated from healthy and diseased tissues and organs represents a key element for personalized medicine approaches. Although biobanks can provide a wide collection of primary and immortalized cells for biomedical research, these do not cover all experimental needs, particularly those related to specific diseases or genotypes. Vascular endothelial cells (ECs) are key components of the immune inflammatory reaction and, thus, play a central role in the pathogenesis of a variety of disorders. Notably, ECs from different sites display different biochemical and functional properties, making the availability of specific EC types (i.e., macrovascular, microvascular, arterial, and venous) essential for designing reliable experiments. Here, simple procedures to obtain high-yield, virtually pure human macrovascular and microvascular endothelial cells from the pulmonary artery and lung parenchyma are illustrated in detail. This methodology can be easily reproduced at a relatively low cost by any laboratory to achieve independence from commercial sources and obtain EC phenotypes/genotypes that are not yet available.
The vascular endothelium lines the inner surface of the blood vessels. It plays key roles in regulating blood coagulation, vascular tone, and immune-inflammatory responses1,2,3,4. Although the culture of endothelial cells (ECs) isolated from human specimens is essential for research purposes, it must be remarked that the ECs from different blood vessels (arteries, veins, capillaries) have specific functions. These cannot be fully recapitulated by human umbilical vein endothelial cells (HUVEC), which are easily available and widely used in studies on vascular endothelium pathophysiology5,6. For instance, human lung microvascular endothelial cells (HLMVECs) play key roles in lung inflammation by controlling leukocyte recruitment and accumulation4,7. Thus, an experimental setting aimed at reproducing lung inflammation with high fidelity should include HLMVECs. On the other hand, EC dysfunction can be observed in several pathologies; therefore, ECs from the patient are fundamental to building a reliable in vitro model of the disease. For instance, the isolation of fragments of ECs from the pulmonary artery (HPAECs), dissected from the explanted lungs of people affected by cystic fibrosis (CF), have enabled us to uncover mechanisms of endothelial dysfunction in this disease8,9.
Thus, protocols aimed at optimizing the isolation of ECs from different sources/organs also in disease states are essential to provide investigators with valuable research tools, particularly when these tools are not commercially available. HLMVEC and HPAEC isolation protocols have been previously reported10,11,12,13,14,15,16,17,18,19. In all cases, the enzymatic digestion of the lung specimens resulted in mixed cell populations, which were purified using ad hoc selective media and magnetic beads- or cytometric-based cell sorting. Further optimizations of these protocols must address two main issues in EC isolation: (1) cell and tissue contamination, which should be resolved at the earliest possible culture passages to minimize EC replicative senescence20; and (2) the low yield of primary EC isolates.
This study describes a new protocol for the high-yield, high-purity isolation of HLMVECs and HPAECs. This procedure can be easily applicable and give virtually pure macrovascular and microvascular ECs in a few steps.
Access restricted. Please log in or start a trial to view this content.
This study was approved, and the protocol followed the guidelines of the human research ethics committee of the University of Chieti-Pescara (#237_2018bis). Figure 1 illustrates the isolation of endothelial cells from segments (1-3 cm long) of pulmonary parenchyma or pulmonary artery from deidentified human subjects (with written consent) undergoing thoracic surgery for various reasons, such as pneumothorax or lobectomy. In this latter case, the surgeons also collected a pulmonary artery segment. Notably, the surgeons were accurately instructed to collect cancer-free samples. The presented protocol was optimized to obtain the greatest possible yield and purity.
1. Experimental preparation
2. Sample preparation
3. Enzymatic digestion
4. Recovery of the digested cells
5. Non-EC removal by filtration
6. Sedimentation of cell clusters and cell seeding
7. Cell expansion
8. Cell sorting
9. Post-sorting expansion
Access restricted. Please log in or start a trial to view this content.
HLMEC isolation
The main problem during the isolation of HLMVECs is the presence of contaminating cells since the microscopic capillaries cannot be easily separated from the stromal tissue. Therefore, achieving the highest possible purity at the earliest stages of the isolation process is crucial in order to reduce the culture passages and, thus, the cell aging. Likewise, an optimal isolation protocol should give the highest possible yield of pure HLMVECs. To achieve these goals, a new procedure wa...
Access restricted. Please log in or start a trial to view this content.
The multiple roles played by vascular endothelial cells in human pathophysiology make these cells an indispensable tool for in vitro pathogenetic and pharmacological studies. Since ECs from different vascular sites/organs display peculiar features and functions, the availability of healthy and diseased ECs from the organ of interest would be ideal for research purposes. For instance, HLMVECs are essential for studies on lung inflammation; therefore, a methodology for the high-yield, high-purity isolation of thes...
Access restricted. Please log in or start a trial to view this content.
The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.
This work was supported by funds from the Italian Ministry of the University and Research (ex 60% 2021 and 2022) to R. P. and by grants from the Italian Cystic Fibrosis Foundation (FFC#23/2014) and from the Italian Ministry of Health (L548/93) to M. R.
Access restricted. Please log in or start a trial to view this content.
Name | Company | Catalog Number | Comments |
0.05% trypsin-EDTA 1X | GIBCO | 25300-054 | Used to detach cells from the culture plates |
Anti CD31 Antibody, clone WM59 | Dako | M0823 | Used for CD-31 staining in immunocytochemistry. Dilution used: 1:50 |
Anti vWF Antibody | Thermo Fisher Scientific | MA5-14029 | Used for von Willebrand factor staining in immunocytochemistry. Working dilution: 1:100 |
Autoclavable surgical scissors | Any | Used for chopping specimens | |
Cell strainers 40 µm | Corning | 431750 | Used during the second filtration |
Cell strainers 70 µm | Corning | 431751 | Using during the first filtration |
Collagenase, Type 2 | Worthington | LS004177 | Type 2 Collagenase used for enzymatic digestion. Working concentration: 2 mg/mL |
Conjugated anti CD31 Antibody | BD Biosciences | 555445 | Used for cell sorting (1:20 dilution) |
Dulbecco′s Phosphate Buffered Saline (PBS) with CaCl2 and MgCl2 | Sigma-Aldrich | D8662 | Used for cell washing before medium change |
Dulbecco′s Phosphate Buffered Saline (PBS) without CaCl2 and MgCl2 | Sigma-Aldrich | D8537 | Used for washing surgical specimens and cells before trypsinization |
Endothelial Cell Growth Medium MV | PromoCell | C-22020 | HLMVEC growth medium |
Fibronectin | Sigma-Aldrich | F0895 | Fibronectin from human plasma used for plate coating. Working concentration: 50 µg/mL |
Gelatin from porcine skin, type A | Sigma-Aldrich | G2500 | Used for plate coating |
Type A gelatin | Sigma-Aldrich | g-2500 | Gelatin from porcine skin used for plate coating. Working concentration: 1.5% |
Access restricted. Please log in or start a trial to view this content.
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved